A phase 1b study of IMU-131 her2/neu peptide vaccine plus chemotherapy in patients with HER2/neu overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction

M. Maglakelidze, T. Yau, I. Bulat, C. Yen, Y. Chao, L. Bai, A. Good, N. Ede, L. Chong, S. Tanasanvimon, C. Charoetum, H. Loong, W. Lausoontornsiri, W. Arpornwirat, J. Maneechavakajon, T. Ungtrakul, W. Chou

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)iv123
JournalAnnals of Oncology
Volume30
DOIs
Publication statusPublished - 2019 Jul

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology

Cite this

Maglakelidze, M., Yau, T., Bulat, I., Yen, C., Chao, Y., Bai, L., Good, A., Ede, N., Chong, L., Tanasanvimon, S., Charoetum, C., Loong, H., Lausoontornsiri, W., Arpornwirat, W., Maneechavakajon, J., Ungtrakul, T., & Chou, W. (2019). A phase 1b study of IMU-131 her2/neu peptide vaccine plus chemotherapy in patients with HER2/neu overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction. Annals of Oncology, 30, iv123. https://doi.org/10.1093/annonc/mdz157.003